Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
Status:
Completed
Trial end date:
2019-12-03
Target enrollment:
Participant gender:
Summary
The main purpose of this study was to demonstrate superiority with regard to overall survival
of avelumab versus docetaxel in participants with programmed death ligand 1 (PD-L1) positive,
non-small cell lung cancer (NSCLC) after failure of a platinum-based doublet.